[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645208":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":47,"collaborators":20,"id":49,"slug":20,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":20,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":20,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"The First Affiliated Hospital of Xiamen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"GPC3-targeted PET\u002FCT","EXPERIMENTAL","Each subject receives a single intravenous injection of GPC3-targeted probe and undergoes PET\u002FCT imaging within the specified time.",[13],"Diagnostic Test: 18F-FDG PET\u002FCT and GPC3-targeted PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","18F-FDG PET\u002FCT and GPC3-targeted PET\u002FCT","Participants will receive a single intravenous injection of 18F-FDG and 68Ga-GPC3, and undergo PET\u002FCT imaging within the specified time.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Liang Zhao","CONTACT","86 18818350620","wzhaoliang01@163.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Haojun Chen","86 18659285282","leochen0821@foxmail.com",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Xiamen","Fujian","361000","China",{"type":39,"coordinates":40},"Point",[41,42],118.08187,24.47979,{"lat":42,"lon":41},[45,46],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},{"type":48,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100645208",false,"NCT07677774","GPC3-Targeted PET\u002FCT in Hepatocellular Carcinoma","Glypian-3 (GPC3)- Targeted PET Imaging in Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with suspected, newly diagnosed, or previously treated hepatocellular carcinoma(supporting evidence may include imaging findings and pathology report);\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n* Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;\n\nExclusion Criteria:\n\n* The inability or unwillingness of the research participant or legal representative to provide written informed consent.\n* Inability to complete PET\u002FCT imaging.","ALL","18 Years","80 Years",{"count":59,"type":60},40,"ESTIMATED","INTERVENTIONAL",[63],"NA","The objective of the study is to evaluate the diagnostic value of GPC3-targeted PET\u002FCT in patients with suspected or histologically\u002Fclinically confirmed hepatocellular carcinoma, and to compare with 18F-FDG PET\u002FCT.",[66,67,9],"Hepatocellular Carcinoma (HCC)","Glypican-3",[69,67,9,70,71],"Hepatocellular Carcinoma","HCC","PET\u002FCT","2026-06-25",{"date":74,"type":75},"2026-07-01","ACTUAL",{"date":77,"type":75},"2026-05-01",{"date":79,"type":60},"2028-05-31",{"name":5,"class":6},1]